Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional ...
– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion – – Exl-111 is a …